Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
National Cancer Institute (NCI)
MultiCare Health System Research Institute
Mayo Clinic
SWOG Cancer Research Network
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Peking Union Medical College Hospital
Tempus AI